Prognostic Value of the Marker P63 in Adenocarcinoma of Lung, Breast, and Pancreas
NCT ID: NCT01942629
Last Updated: 2013-09-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
300 participants
OBSERVATIONAL
2013-10-31
2015-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Various studies proved p63 as a marker of basal cells in normal salivary glands, breast, prostate, respiratory and squamous epithelia, and of tumor cells from various malignancies. Still, p63 has been the subject of relatively few studies in lung adenocarcinoma, and breast carcinoma, and no study has described the correlation of p63 with pancreatic ductal adenocarcinoma.
In the current study, we aim to evaluate the prognostic value of the expression of p63 in the lung adenocarcinoma, breast adenocarcinoma, and pancreatic ductal adenocarcinoma. We will achieve this aim by collecting clinical data retrospectively from the patients' medical records as well as assessing the histological sections and performing immunohistochemical staining for p63.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Lung adenocarcinoma
This group will include 100 patients with lung adenocarcinoma, the clinical outcomes will be retrospectively assessed.
at the same time 2 histopathological slides will be retrieved and stained for known markers as well as to P63.
their will be no intervention in any of the groups, the study is retrospective
Breast adenocarcinoma
This group will include 100 patients with breast adenocarcinoma, the clinical outcomes will be retrospectively assessed.
at the same time 2 histopathological slides will be retrieved and stained for known markers as well as to P63.
their will be no intervention in any of the groups, the study is retrospective
Pancreatic ductal adenocarcinoma
This group will include 100 patients with pancreatic ductal adenocarcinoma, the clinical outcomes will be retrospectively assessed.
at the same time 2 histopathological slides will be retrieved and stained for known markers as well as to P63.
their will be no intervention in any of the groups, the study is retrospective
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
their will be no intervention in any of the groups, the study is retrospective
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Available histopathological diagnosis of the malignancy.
Exclusion Criteria
* Patients with second primary tumor.
* Patients with pathological blocks not enough for future slicing.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Rambam Health Care Campus
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
SHOROOK NA'ARA MD
MD
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0298-13ctil
Identifier Type: -
Identifier Source: org_study_id